Botanix collaborator Dr Mark Blaskovich of the University of Queensland presented new antimicrobial data at ASM Microbe 2019, highlighting cannabidiol as a remarkably active Gram-Positive antibiotic
Key highlights
- Botanix collaborator Dr Mark Blaskovich of the University of Queensland presented new antimicrobial data at ASM Microbe 2019, highlighting cannabidiol as a remarkably active Gram-Positive antibiotic
- Dr Blaskovich’s poster presentation was selectively highlighted as significant new research and was the subject of a separate press release from the conference organisers
- Antimicrobial resistance represents a significant market opportunity and the BTX 1801 data supports Botanix’s position as a leading developer of treatments for skin diseases
Philadelphia PA and Sydney Australia, 24 June 2019: Clinical stage cannabinoid company Botanix Pharmaceuticals (“Botanix” or “the Company”) is pleased to announce Dr Mark Blaskovich presented the antimicrobial data, from studies recently conducted with Botanix’s antimicrobial product BTX 1801, at the American Society for Microbiology (ASM) Microbe 2019 Conference. The conference organisers also released a press release specifically highlighting the research breakthrough and will be available on the Company’s website: https://www.botanixpharma.com/investors/
Dr Blaskovich’s presentation entitled ‘Cannabidiol is a Remarkably Active Gram-Positive Antibiotic’, outlined the following data:
- Cannabidiol is a broad-spectrum Gram-Positive antibiotic which is effective against a range of problematic human and animal bacteria
- Cannabidiol is effective against clinical isolates of staphylococcus aureus (“staph”) and methicillin resistance staphylococcus aureus (“MRSA”)
- Bacteria do not form resistance to cannabidiol
- Cannabidiol kills bacteria very quickly
- Cannabidiol disrupts biofilms that bacteria use to protect themselves
- BTX 1801 is effective in animal models of wound infection
The studies were conducted in collaboration with Dr Mark Blaskovich at The University of Queensland’s Institute for Molecular Bioscience’s Centre for Superbug Solutions and supported by Innovation Connections, an Australian Government grant.
ASM Microbe 2019 is taking place on 20 to 24 June 2019 in San Francisco, US and is the largest gathering of microbiologists and industry globally. With a member base of over 30,000, the conference is expected to attract over 8,000 attendees and more than 260 companies this year.
| Matt Callahan, Founder and Executive Director of Botanix said: “The anti-inflammatory and antimicrobial capabilities of cannabidiol underpins Botanix’s ability to target a range of skin diseases and infections. This is reflected by our new antimicrobial data being selected to feature as significant new research at ASM Microbe 2019. ” |
About Botanix Pharmaceuticals
Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage cannabinoid company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company’s focus is the development of safe and effective topical treatments for acne, psoriasis, atopic dermatitis and other skin conditions. The active ingredient contained in Botanix products is a synthetic form of cannabidiol. Treatment targets include inflammation, deterioration of the of the skin barrier, skin cell proliferation, pruritus (itch), excess sebum production and bacterial infection.
Botanix has an exclusive license to use a proprietary drug delivery system (PermetrexTM) for direct skin delivery of active pharmaceuticals in all skin diseases. Botanix is working with multiple parties to test the application of PermetrexTM on both a fee-for-service and traditional license basis. Botanix pursues a rapid clinical development strategy aimed at accelerating product commercialisation.
The Company completed its first acne patient studies with BTX 1503 in January 2018 and has commenced a Phase 2 clinical study in June 2018 with study completion expected in 3Q CY2019. The BTX 1204 atopic dermatitis Phase 2 patient study is also underway with study completion expected in 4Q CY2019. Finally, Phase 1b BTX 1308 psoriasis mechanism of action study has recently completed, with positive interim data announced in June 2019. Pipeline developments that leverage the antimicrobial properties of cannabidiol are also moving forward and are planned to enter the clinic in 2H CY2019.
To learn more please visit: https://www.botanixpharma.com/
For more information, please contact:
General enquiries Matt Callahan Botanix Pharmaceuticals Founder & Executive Director +1 215 767 4184 | Investor enquiries Joel Seah Vesparum Capital P: +61 3 8582 4800 | Media enquiries Haley Chartres Hales2 Consultancy P: +61 423 139 163 |
